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Introduction: Ex vivo-expanded autologous myoblasts are being used in clinical trials for the 
treatment of various skeletal muscle conditions, including stress urinary incontinence caused by 
urethral sphincter damage. The use of fetal calf serum (FCS) as a growth media supplement in 
these procedures still raises various technical and ethical concerns. As an alternative to 
xenogeneic supplements, human platelet lysate (hPL) has recently gained increasing attention 
for ex vivo expansion of mesenchymal stem cells in clinical studies. However, little is known 
regarding the ability of hPL to support ex vivo expansion of skeletal myogenic precursors. 
Aim: The aim of this study was to assess the performance of hPL for the isolation and expansion 
of human skeletal myoblasts in comparison to FCS. 
Materials and methods: Skeletal myoblasts were isolated and expanded in a commercial 
medium formulation (MyoTonic, Cook Myosite) supplemented with either 10% FCS or 5% pooled 
hPL (Stemulate, Cook Regentec). Cells were assessed during multiple passage expansion by 
analysis of cell proliferation, cellular phenotype, and gene expression profiles. The ability of media 
to preserve the differentiation capacity of the cells was evaluated in cells from early and late 
passages by immunocytochemistry and qRT-PCR after induction with MyoTonic medium 
supplemented with 2% horse serum. 
Results: Analysis of cell proliferation over five passages revealed that myoblasts cultured in hPL-
supplemented medium displayed a significantly higher cumulative cell number over time, due to 
consistently larger growth rate. Cells grown in hPL media evidenced a lower activation during 
propagation, as revealed by a significantly lower transcription of the skeletal myogenic factors 
MYF5 and MYOD. The percentage of CD56 positive cells appeared to decrease over time with 
passaging irrespective of the media type, suggesting a progressive depletion of myogenic 
precursors over time. Nevertheless, the cells expanded in hPL evidenced a robust capacity for 
differentiation at early (P1) and late passages (P5), as demonstrated by the formation of myosin-
rich mature myotubes displaying high levels of myogenin activation. 
Conclusions: Our results suggest that the hPL supplemented medium supports isolation and 
efficient expansion of skeletal myoblasts while preserving their differentiation capacity. In 
perspective, hPL may represent an efficient alternative to FCS for the ex vivo expansion of 
myoblasts aimed for cell based therapies. 
 
